| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
140,990,000 |
| Market
Cap: |
73.88(M) |
| Last
Volume: |
2,041,307 |
Avg
Vol: |
1,748,484 |
| 52
Week Range: |
$0.2971 - $1.74 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Sangamo BioSciences is a clinical-stage genomic medicine company focused on translating science into medicines. Co.'s clinical-stage product candidates are: Isaralgagene civaparvovec (ST-920), which is Co.'s wholly-owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, which is Co.'s zinc finger nuclease gene-edited cell therapy product candidate for the treatment of sickle cell disease; TX200 for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and Giroctocogene fitelparvovec (SB-525), which is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
11,784 |
| Total Buy Value |
$0 |
$0 |
$0 |
$43,025 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
6,000,000 |
6,500,000 |
| Total Sell Value |
$0 |
$0 |
$3,000,000 |
$5,657,240 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
1 |
3 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mcclung David Mark |
EVP, Chief Operating Officer |
• – – |
2023-02-25 |
4 |
D |
$2.66 |
$25,922 |
D/D |
(9,745) |
224,774 |
|
- |
|
| Duraibabu Prathyusha |
SVP, Chief Financial Officer |
• – – |
2023-02-25 |
4 |
D |
$2.66 |
$18,700 |
D/D |
(7,030) |
133,725 |
|
- |
|
| Willoughby Scott B. |
SVP, Gen. Counsel & Secretary |
• – – |
2023-02-25 |
4 |
D |
$2.66 |
$13,640 |
D/D |
(5,128) |
130,589 |
|
- |
|
| Ramelmeier Rolf Andrew |
EVP, Technical Operations |
• – – |
2023-02-25 |
4 |
D |
$2.66 |
$41,544 |
D/D |
(15,618) |
173,217 |
|
- |
|
| Dubois-Stringfellow Nathalie |
SVP-Chief Development Officer |
• – – |
2023-02-25 |
4 |
D |
$2.66 |
$26,158 |
D/D |
(9,834) |
138,558 |
|
- |
|
| Macrae Sandy |
President, CEO and Director |
• • – |
2023-02-25 |
4 |
D |
$2.66 |
$145,680 |
D/D |
(54,767) |
623,709 |
|
- |
|
| Fontenot Jason D. |
SVP, Chief Scientific Officer |
• – – |
2023-02-25 |
4 |
D |
$2.66 |
$17,447 |
D/D |
(6,559) |
139,358 |
|
- |
|
| Mcclung David Mark |
EVP, Chief Operating Officer |
• – – |
2023-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
56,250 |
234,519 |
|
- |
|
| Duraibabu Prathyusha |
SVP, Chief Financial Officer |
• – – |
2023-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
53,438 |
140,755 |
|
- |
|
| Willoughby Scott B. |
SVP, Gen. Counsel & Secretary |
• – – |
2023-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
42,750 |
135,717 |
|
- |
|
| Ramelmeier Rolf Andrew |
EVP, Technical Operations |
• – – |
2023-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
188,835 |
|
- |
|
| Dubois-Stringfellow Nathalie |
SVP-Chief Development Officer |
• – – |
2023-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
53,438 |
148,392 |
|
- |
|
| Macrae Sandy |
President, CEO and Director |
• • – |
2023-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
157,300 |
678,476 |
|
- |
|
| Fontenot Jason D. |
SVP, Chief Scientific Officer |
• – – |
2023-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
42,750 |
145,917 |
|
- |
|
| Beers Courtney |
Director |
– • – |
2022-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
18,750 |
18,750 |
|
- |
|
| Horn Margaret A |
Director |
– • – |
2022-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
18,750 |
18,750 |
|
- |
|
| Dubois-Stringfellow Nathalie |
SVP-Chief Development OfficerO |
• – – |
2022-09-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
94,954 |
|
- |
|
| Biogen Ma Inc. |
10% Owner |
– – • |
2022-08-30 |
4 |
S |
$5.27 |
$526,520 |
I/I |
(100,000) |
23,652,466 |
|
- |
|
| Biogen Ma Inc. |
10% Owner |
– – • |
2022-08-29 |
4 |
S |
$5.33 |
$2,130,720 |
I/I |
(400,000) |
23,752,466 |
|
- |
|
| Willoughby Scott B. |
SVP, Gen. Counsel & Secretary |
• – – |
2022-08-13 |
4 |
D |
$6.33 |
$5,469 |
D/D |
(864) |
92,966 |
|
- |
|
| Mcclung David Mark |
EVP, Chief Operating Officer |
• – – |
2022-06-25 |
4 |
D |
$4.31 |
$49,673 |
D/D |
(11,525) |
175,816 |
|
- |
|
| Duraibabu Prathyusha |
SVP, Chief Financial Officer |
• – – |
2022-06-11 |
4/A |
D |
$3.76 |
$3,249 |
D/D |
(864) |
86,595 |
|
- |
|
| Markels John |
Director |
– • – |
2022-06-03 |
4 |
B |
$3.69 |
$25,029 |
D/D |
6,784 |
32,484 |
2.39 |
- |
|
| Parker H Stewart |
Director |
– • – |
2022-06-01 |
4 |
B |
$3.60 |
$17,996 |
D/D |
5,000 |
48,700 |
2.39 |
- |
|
| Willoughby Scott B. |
SVP, Gen. Counsel & Secretary |
• – – |
2022-04-29 |
4 |
D |
$4.15 |
$581 |
D/D |
(140) |
90,709 |
|
- |
|
1096 Records found
|
|
Page 3 of 44 |
|
|
0.04 (6.83%) 
